RNA — Avidity Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $11.27bn
- $9.40bn
- $10.90m
Annual cashflow statement for Avidity Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -118 | -174 | -212 | -322 | -685 |
| Depreciation | |||||
| Non-Cash Items | 17.7 | 27.5 | 29.9 | 33.2 | 89.7 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 4.88 | 8.83 | 61.1 | -14.6 | -59.7 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -94.8 | -136 | -119 | -301 | -650 |
| Capital Expenditures | -3.74 | -2.82 | -4.23 | -7.07 | -17.4 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -78.8 | -187 | -126 | -847 | -20.6 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -82.5 | -190 | -130 | -854 | -38 |
| Financing Cash Flow Items | -11.3 | — | — | — | -12.4 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 176 | 346 | 93.9 | 1,192 | 851 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -1.01 | 19.9 | -155 | 37.3 | 163 |